Bar-Tana Jacob
Department of Human Nutrition and Metabolism, Hebrew University-Hadassah Medical School, PO Box 12272, Ein Kerem, Jerusalem 91120, Israel.
Curr Opin Investig Drugs. 2004 Sep;5(9):941-6.
This critical review examines the putative role played by peroxisome proliferator-activated receptor alpha (PPARalpha) in the hypolipidemic activity induced by peroxisome proliferators/PPARalpha agonists. The hypolipidemic effect of peroxisome proliferators mediated in rodents by hepatic PPARalpha activation is independent of PPARalpha in humans, and is transduced by direct suppression of hepatocyte nuclear factor-4alpha by the CoA-thioesters of hypolipidemic peroxisome proliferators. A novel target for hypolipidemic drugs in humans and an updated risk assessment for human hypolipidemic drugs are implied.
这篇批判性综述探讨了过氧化物酶体增殖物激活受体α(PPARα)在过氧化物酶体增殖物/PPARα激动剂诱导的降血脂活性中所起的假定作用。在啮齿动物中,过氧化物酶体增殖物通过激活肝脏PPARα介导的降血脂作用在人类中与PPARα无关,而是由降血脂过氧化物酶体增殖物的辅酶A硫酯直接抑制肝细胞核因子-4α来传导。这暗示了人类降血脂药物的一个新靶点以及对人类降血脂药物的更新风险评估。